|Bid||6.49 x 1400|
|Ask||6.64 x 800|
|Day's Range||6.09 - 6.59|
|52 Week Range||2.25 - 7.35|
|Beta (5Y Monthly)||-0.75|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov. 10, 2021 - Nov. 15, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.49|
These two top Canadian healthcare stocks are both analyst favourites and offer some of the best growth potential of any investment on the market today. The post 2 Canadian Healthcare Stocks That Are All-Stars in the Making appeared first on The Motley Fool Canada.
BELLUS (BLU) completes enrollment in the mid-stage studies for refractory chronic cough and chronic pruritus associated with atopic dermatitis.
LAVAL, Quebec, September 23, 2021--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders, today announced that the Company has completed patient enrollment in the Phase 2b SOOTHE clinical trial of BLU-5937 in refractory chronic cough ("RCC") and the Phase 2a BLUEPRINT clinical trial of BLU-5937 in chronic prur